|
Note 7 - Prepaid Expenses
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid Expenses And Other Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid Expenses And Other Assets [Text Block] | 7. Prepaid expenses Prepaid expenses as of December 31, 2014 and 2013 consisted of the following (in thousands):
As of December 31, 2014 and 2103, prepaid research and development expenses includes $2.5 million and $2.7 million, respectively for upfront fees paid to our primary clinical research organization assisting with our clinical trials. The upfront fees will be relieved in future periods based upon work completed. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||